GHK-Cu Peptide
A tripeptide from your own plasma that refuses to travel without its copper atom. The strongest card in its file is a 1994 topical gel trial, and the one blinded aesthetic trial found no objective benefit.
Choose your pack
For research use only. Not for human or veterinary use.
What GHK-Cu Peptide is
The plain-language version, first.
Three residues found in your blood in 1973, permanently holding a copper ion.
GHK-Cu is a complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine with copper two, chelated through the histidine imidazole and the peptide backbone, the free tripeptide being C14H24N6O4 at molar mass 340.38, CAS 49557-75-7. Every credible human study of it has used a topical formulation, and in 2026 the FDA kept the injectable route outside its enforcement discretion.
GHK-Cu has the best origin credentials in the cosmetic-peptide world: it was found in actual human plasma, in 1973, doing its thing without anyone's help.
Glycine-histidine-lysine, plus a copper ion it binds so avidly that the copper is part of the name.
Plasma levels decline with age, which handed the marketing industry its favourite sentence, and the compound became the backbone of forty years of copper-peptide skincare.
Underneath the cosmetics empire is real chemistry: a genuine copper-binding motif with legitimate enzymatic relevance.
A real molecule with a real decline curve and a cosmetics industry built on the gap between those facts and proof. The research section keeps score honestly.
What is GHK-Cu?
Mechanism studied, not outcome promised.
Copper is a required cofactor for lysyl oxidase, which crosslinks collagen and elastin. GHK binds it avidly and that pairing is the mechanism.
GHK-Cu penetrates the stratum corneum poorly. It is hydrophilic and charged, and the skin barrier is built to exclude exactly that. Reviews name this as unresolved.
Copper logistics for the enzymes that build skin's scaffolding.
Copper is a working cofactor for enzymes that matter to skin structure, including lysyl oxidase, which cross-links collagen and elastin into functional scaffolding.
The GHK motif binds copper tightly and is proposed as a delivery courier: peptide carries ion, enzymes get supplied, scaffolding work proceeds.
There is also cell-culture work on gene expression effects that the enthusiast literature quotes heavily.
As mechanisms go it is chemically grounded, and topical delivery sidesteps this shelf's usual stomach problem.
Here's the honest part, and it is a tale of two trials below.
A plausible courier mechanism, tested properly roughly twice in three decades, with a split decision.
The research so far for GHK-Cu Peptide
Where the evidence is thin, we say so.
A 1994 multicentre randomised vehicle-controlled gel trial in diabetic neuropathic plantar ulcers, reporting 98.5 percent median area closure against 60.8 percent and ulcer infection 7 percent against 34 percent.
Nothing. No registered injectable trial, no published human data by that route, and an explicit FDA statement that human data are limited for it.
In 2026 FDA placed injectable GHK-Cu in its significant safety risks category, writing that compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations. When non-injectable GHK-Cu was later restored to enforcement discretion, it was restored as GHK-Cu except for injectable routes of administration.
One decent 1994 trial, one blinded null result, and a cosmetics industry in between.
Forty years of cosmetic marketing rests on remarkably few controlled tests, and the two best ones disagree.
The 1994 trial: a topical gel study in wound settings with genuinely positive findings. The strongest card in the file.
The blinded aesthetic trial: objective instrumental measures found no benefit over vehicle. The one time the cosmetic claim faced blinding, it did not show up.
Everything else is cell work, small open-label studies, and industry-adjacent publications.
Nothing approved as a drug anywhere.
One old win in wounds, one modern null in aesthetics, and an industry quoting only the first. Both results are real. Both belong on the page.
GHK-Cu vial sizes and current stock are listed below.
GHK-Cu Peptide specs
The chemistry, exactly as released.
Who studies GHK-Cu Peptide
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Wound care
Diabetic neuropathic plantar ulcers, where the 1994 randomised vehicle-controlled gel trial produced the strongest result this compound has.
Dermatology and cosmetic science
Widely used as Copper Tripeptide-1, though the one blinded aesthetic trial found no objective improvement in wrinkles or skin quality in 13 patients.
Matrix biology
Lysyl oxidase, collagen and elastin crosslinking, and the role of copper as a required cofactor in connective tissue assembly.
Regulatory reviewers
FDA treated the injectable route separately from every other route in 2026, which is an unusual and deliberate distinction worth understanding.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
GHK-Cu Peptide backstory
How it got here.
GHK was identified in human plasma during work on factors that influenced liver cell behaviour in culture, and the copper binding was recognised as central to its activity rather than incidental. The medical development went into wound care.
Chronic wounds, particularly diabetic foot ulcers, are a serious clinical problem, and a copper-carrying peptide that promotes matrix remodelling was a rational candidate. That produced the 1994 trial, which remains the strongest evidence for the compound.
The cosmetic industry adopted it separately, as Copper Tripeptide-1, on the strength of the mechanism and the wound data rather than on dedicated aesthetic trials. The 2006 study is one of very few blinded aesthetic evaluations and it did not find an objective effect.
The injectable market is more recent still, and has no clinical literature behind it at all.
- 1
Found in plasma
Glycyl-histidyl-lysine was identified in human plasma and its high affinity copper binding recognised as central rather than incidental to its activity.
- 2
Developed for wounds
Chronic diabetic foot ulcers were the medical target, producing the 1994 multicentre gel trial that remains the strongest evidence for the compound.
- 3
Adopted cosmetically, then injected
The cosmetic industry took it up as Copper Tripeptide-1 on mechanism and wound data rather than aesthetic trials. The injectable market came later, with no clinical literature at all.
Buying GHK-Cu Peptide in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
Route is the whole question here
The evidence for this compound is topical. A 1994 wound gel trial is its best result. FDA specifically excluded injectable routes when it restored the rest of GHK-Cu to enforcement discretion in May 2026, and said human data are limited for that route.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.
Stuff people ask about GHK-Cu Peptide
If your question is not here, email us. Real human answers.
No published human data by that route that we could find, and no registered injectable trial. The clinical trial registry returns one GHK study of any kind, a topical gel trial that began recruiting in February 2026. FDA stated in 2026 that there are limited data in humans to inform safety-related considerations for compounded injectable GHK-Cu.
It placed injectable GHK-Cu in its category for substances that may present significant safety risks, citing potential immunogenicity from aggregation and peptide-related impurities. The nominations were later withdrawn by the nominators, and when non-injectable GHK-Cu was restored to enforcement discretion in May 2026 it was restored specifically as GHK-Cu except for injectable routes of administration. FDA has said it intends to consult its advisory committee on the substance before the end of February 2027.
A 1994 multicentre, randomised, evaluator-blinded, vehicle-controlled trial in diabetic neuropathic plantar ulcers using a topical gel, published in Wound Repair and Regeneration. It reported 98.5 percent median area closure against 60.8 percent for vehicle, a larger effect in ulcers over 100 square millimetres, and ulcer infection in 7 percent against 34 percent.
The one blinded aesthetic trial did not find an objective effect. Miller and colleagues in 2006 studied topical copper tripeptide complex after carbon dioxide laser resurfacing with blinded evaluators and 13 patients completing. There was no significant difference in erythema resolution and no significant improvement in wrinkles or overall skin quality by objective evaluation. The only significant result was patient-reported satisfaction. A 2025 review noted a surprising absence of clinical studies for this use despite widespread cosmetic adoption.
Because copper is a required cofactor for lysyl oxidase, the enzyme that forms the covalent crosslinks holding collagen and elastin fibres together. GHK binds copper with high affinity and the complex is studied as a way of delivering it into tissue while modulating matrix turnover genes. The copper is not a carrier or a salt, it is part of the mechanism.
GHK-Cu is hydrophilic and carries charge, and the stratum corneum is specifically built to exclude molecules like that. Reviews of the topical anti-wrinkle literature name poor stratum corneum permeation as an unresolved formulation issue, which is a limitation on the route that has all of the compound evidence behind it.
Good pairing options with GHK-Cu Peptide
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as GHK-Cu Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Without a zinc atom it is completely inert. Not less active. Inert. The metal is not a supporting player here, it is half the molecule's identity.
It has no sequence and no CAS number, because it is not a molecule. It is an extract of calf thymus, still in clinical use across Russia, and that combination is genuinely unusual.
Order GHK-Cu Peptide right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching GHK-Cu Peptide and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for GHK-Cu Peptide
Other names for the same compound.